 |
32 Diseases |  |
11 Trials |
|
11 Trials |  |
1696 News |  |
| «12...89101112131415161718...2021» |
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] VIROLOGIC OUTCOMES BY RESISTANCE CATEGORY AND PRETREATMENT IN THE DUALIS STUDY ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_876;
No emergence of RAMs during follow-up was observed. As shown in the DUALIS study, dual therapy with DTG+bDRV tends to be an effective treatment option with no treatment-emergent resistance for PLWH on suppressive first- or further-line ART with or without evidence of pre-existing NRTI, NNRTI or PI RAMs.
- Prezista (darunavir) / J&J, lamivudine / Generic mfg.
[VIRTUAL] CLINICAL OUTCOMES OF 2-DRUG REGIMENS (2DRS) VS 3-DRUG REGIMENS (3DRS) IN HIV ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_870;
After accounting for demographic and clinical characteristics, there was a similar incidence of non-AIDS events on 2DRs and 3DRs, however confounding by indication cannot be excluded. With a median follow-up of 1.7 years, 2DRs appear to be a viable treatment option with regard to clinical outcomes, although further research on long-term durability and potential toxicities of 2DRs is needed.
- Prezista (darunavir) / J&J, emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
[VIRTUAL] ADVANCED GLYCATION END PRODUCTS ASSOCIATED WITH CARDIOMETABOLIC RISK ON ART ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_555;
Initiation of ART seems to increase levels of AGEs in ART-nave participants with HIV, regardless of regimen used. Accumulation of AGEs is independently associated with subsequent cardiometabolic risk while on ART.
- [VIRTUAL] HEPATIC STEATOSIS ASSOCIATED WITH EXPOSURE TO ELVITEGRAVIR AND RALTEGRAVIR ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_534;
Moderate-severe hepatic steatosis in PLWH without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir and raltegravir. Prospective trials are required to establish a causal association.
- Prezista (darunavir) / J&J, lamivudine / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
[VIRTUAL] EMULATION OF AN RCT OF DOLUTEGRAVIR VS BOOSTED-DARUNAVIR IN ADVANCED ART NAIVE ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_507;
Calendar year of starting was a key factor but results were consistent across periods of ART initiation. Under the assumptions of no unmeasured confounding and correct model specification, our analysis suggests that a RCT conducted in the target population of ART-nave patients with CD4 count<200 or AIDS is likely to show a notable reduction in risk of treatment failure in people initiated with dolutegravir vs. boosted-darunavir based therapies.
- Prezista (darunavir) / J&J
[VIRTUAL] PLASMA & INTRACELLULAR PK AND RENAL SAFETY OF TAF 25MG WITH BOOSTED PI AND LDV/SOF ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_496;
Ledipasvir/sofosbuvir (LDV/SOF) is a recommended therapy for Hepatitis C virus (HCV)...Ten participants (1 black female; 9 males [5 Hispanic, 4 white]) were enrolled; 9 were on darunavir (5 RTV, 4 COBI) and 1 on atazanavir/RTV...Unlike prior findings with TDF, adding LDV/SOF with TAF did not significantly increase plasma TFV or TFV-DP in PBMC. This is likely due to differences in hydrolysis pathways between TDF and TAF, and reassures on the safety of TAF + b/PI + LDV/SOF in HIV/HCV-coinfected patients.
- Prezista (darunavir) / J&J
[VIRTUAL] AGING DOES NOT IMPACT DRUG-DRUG INTERACTION MAGNITUDES INVOLVING ANTIRETROVIRAL DRUGS ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_495;
PBPK modelling in combination with limited clinical data demonstrated that DDI magnitudes with ARVs appear not to be impacted by aging. Thus, in the absence of severe comorbidities, management of DDIs can be similar in elderly compared to young PLWH.
- Prezista (darunavir) / J&J, Vemlidy (tenofovir alafenamide) / Gilead, Vitekta (elvitegravir) / Japan Tobacco, Gilead
[VIRTUAL] UTILITY OF MINIMALLY INVASIVE SPECIMENS TO INFORM ARV ADHERENCE TEST DEVELOPMENT ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_492;
Development of POC tests to detect ARV drugs from minimally invasive specimens may be attractive to assess adherence. Our results suggest that POC assays targeting TFV, FTC or DRV in urine or FTC, EVG or DRV in whole blood may provide the most reliable indicators of ARV adherence.
- Prezista (darunavir) / J&J
[VIRTUAL] IMMUNOLOGICAL AND CYTOKINE CHANGES IN BLOOD AND GUT MUCOSA FROM PHI BY AN EARLY ART ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_432;
P3
In addition, levels of Th1 (IFN-, IL-12, MIP-1), Th2 (IL-4, IL-10) and Th17 cytokines and chemokines decreased similarly in both cases and controls at w48. An extremely early and intensified ART in PHI patients allowed good immunological reconstitution, decreased immune activation and reduced inflammatory profile in different body compartments.
- [VIRTUAL] CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_366;
Both CAB and RPV have a low drug interaction potential as perpetrators. Alternative ART selection after discontinuing CAB LA + RPV LA may include CYP3A and/or UGT1A1 inducers or inhibitors, without efficacy or safety concerns despite potential for transient increases in CAB and RPV concentrations by inhibitors.
- ||| Prezista (darunavir) / J&J
New trial: Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA (clinicaltrials.gov) - Feb 13, 2020
P=N/A, N=44, Completed, Sponsor: Geropharm
- | Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Trial completion date, Combination therapy: DRIVE-SHIFT: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (clinicaltrials.gov) - Feb 11, 2020
P3, N=673, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Alternative ART selection after discontinuing CAB LA + RPV LA may include CYP3A and/or UGT1A1 inducers or inhibitors, without efficacy or safety concerns despite potential for transient increases in CAB and RPV concentrations by inhibitors. Trial completion date: Nov 2021 --> Aug 2022
- | Journal: Erratum to: Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. (Pubmed Central) - Feb 6, 2020
Trial completion date: Nov 2021 --> Aug 2022 No abstract available
- |||| remdesivir (GS-5734) / Gilead, Prezista (darunavir) / J&J
There's a proliferation of HIV protease inhibitor trials for #2019nCoV. In addition to the remdesivir trial, I count 8 (!!) registered RCTs studying either lopinavir or darunavir. There's no standard inclusion criteria or outcome, but they all appear focused on mild/mod disease (Twitter) - Feb 5, 2020
- Discovery of a novel sensory pathway to detect pathogens in the cerebrospinal fluid during bacterial meningitis (Arena 4) - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_4139;
Figure 1. A.
- || Prezista (darunavir) / J&J, emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Clinical, Clinical data, Journal: Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation. (Pubmed Central) - Jan 31, 2020
Conclusion and Relevance: Although providing a regimen containing ≤2 active drugs, the use of once-daily DRV/r plus TDF/FTC in treatment-experienced patients with single-/multiclass resistant virus resulted in virological suppression in more than three-fourths of patients. These retrospective data suggest that despite the presence of an M184V/I, this combination may be an option in patients seeking a once-daily ARV therapy to improve adherence.
- || Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report. (Pubmed Central) - Jan 31, 2020
Physiological changes during pregnancy can affect pharmacokinetics and reduce a mother's bioavailability of antiretroviral drugs, potentially altering their pharmacological activity. A personalized treatment and a careful follow-up are hence mandatory for this key population.
- | Prezista (darunavir) / J&J
Observational data, Journal: Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study. (Pubmed Central) - Jan 29, 2020
A personalized treatment and a careful follow-up are hence mandatory for this key population. Our data show a favorable effect of EVG/c/FTC/TDF switch to preserve immune activation-driven damage to T cell homeostasis, restore the multifunctional properties of effector T cells, and possibly contain cell-associated HIV viral burden in already virologically suppressed patients.
- ||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (clinicaltrials.gov) - Jan 28, 2020
P3, N=578, Completed, Sponsor: Gilead Sciences
Our data show a favorable effect of EVG/c/FTC/TDF switch to preserve immune activation-driven damage to T cell homeostasis, restore the multifunctional properties of effector T cells, and possibly contain cell-associated HIV viral burden in already virologically suppressed patients. Active, not recruiting --> Completed
- || Prezista (darunavir) / J&J, lopinavir/ritonavir / Generic mfg.
PIs for coronavirus: Would you stick with lopinavir/ritonavir or use a “newer” combination Darunavir/r for example? @CarlosdelRio7 @BrendaCrabtreeR @PaulSaxMD (Twitter) - Jan 25, 2020
- || Enrollment closed, Trial primary completion date: RESIST-2: 2nd-line ART for HIV-2 Infection (clinicaltrials.gov) - Jan 22, 2020
P=N/A, N=150, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2022 --> May 2020
- | Prezista (darunavir) / J&J
Clinical, Observational data, Journal, Adverse events: Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study. (Pubmed Central) - Jan 21, 2020
Models that also adjusted for previous ARV exposure showed no statistically significant association between any-type CVAEs and either DRV doses, 1,200 or 800 mg/daily (as also suggested by propensity score stratification), or previous DRV exposure duration. We found no evidence of a relationship between DRV use and increased CV risk.
- | Prezista (darunavir) / J&J
Enrollment open: A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants (clinicaltrials.gov) - Jan 2, 2020
P1, N=28, Recruiting, Sponsor: Janssen Research & Development, LLC
We found no evidence of a relationship between DRV use and increased CV risk. Not yet recruiting --> Recruiting
- || Prezista (darunavir) / J&J
Clinical, Journal: Once-daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS-165 DARULIGHT study. (Pubmed Central) - Jan 1, 2020
Not yet recruiting --> Recruiting No abstract available
- || Prezista (darunavir) / J&J, ritonavir / Generic mfg., Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
CURED OF ME/CFS ON CONTINUOUS DAILY HIV AIDS DOSE OF HAART PREZISTA NORVIR BIKTARVY FOR XMRV MLV RUSCETTI (HTLV CODISCOVERER) MIKOVITS (HIV RESEARCHER) RETROVIRUS USING DISCOVERY PCR TECHNIQUES (Twitter) - Dec 25, 2019
- | Prezista (darunavir) / J&J
Journal: Characterisation of protease resistance mutations in a South African paediatric cohort with virological failure, 2011 - 2017. (Pubmed Central) - Dec 25, 2019
We observed a high rate of PI resistance mutations, with a resulting loss of PIs that could be used in construction of third-line regimens. To build on improvements from the introduction of antiretroviral therapy, increased efforts are needed by both health professionals and caregivers to improve adherence measures in children perinatally infected with HIV.
- || Selzentry (maraviroc) / ViiV Healthcare, Prezista (darunavir) / J&J
Clinical, Journal: The effect of switching to Maraviroc + Darunavir/ritonavir dual therapy in virologically suppressed patients on the progression of liver fibrosis: findings from a randomized study. (Pubmed Central) - Dec 23, 2019
To build on improvements from the introduction of antiretroviral therapy, increased efforts are needed by both health professionals and caregivers to improve adherence measures in children perinatally infected with HIV. No abstract available
- | Prezista (darunavir) / J&J
New P1 trial: A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants (clinicaltrials.gov) - Dec 22, 2019
P1, N=28, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Prezista (darunavir) / J&J
Journal: Structural Adaptation of Darunavir Analogs Against Primary Mutations in HIV-1 Protease. (Pubmed Central) - Dec 21, 2019
Collective analysis of protease-inhibitor interactions in the crystal structures using principle component analysis was able to distinguish inhibitor identity and relative potency solely based on vdW contacts. Our results reveal the complexity of the interplay between inhibitor P1' moiety and S1' mutations, and validate principle component analyses as a useful tool for distinguishing resistance and inhibitor potency.
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open: Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) - Dec 19, 2019
P4, N=300, Recruiting, Sponsor: Kirby Institute
Our results reveal the complexity of the interplay between inhibitor P1' moiety and S1' mutations, and validate principle component analyses as a useful tool for distinguishing resistance and inhibitor potency. Not yet recruiting --> Recruiting
- ||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date: Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (clinicaltrials.gov) - Dec 10, 2019
P3, N=578, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial completion date: Jul 2020 --> Dec 2019
- ||| Tybost (cobicistat) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Trial completion date, Trial primary completion date: Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (clinicaltrials.gov) - Nov 22, 2019
P2/3, N=100, Recruiting, Sponsor: Gilead Sciences
Trial completion date: Jul 2020 --> Dec 2019 Trial completion date: Dec 2024 --> Apr 2026 | Trial primary completion date: Dec 2020 --> Oct 2021
- | Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. (Pubmed Central) - Nov 21, 2019
The investigated dual therapy was effective and safe. The observed increase in lipid parameters only concerned the patients who had used a TDF-based regimen prior to analysed dual treatment.
- | Prezista (darunavir) / J&J, emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Journal: Changes in the Fungal Marker β-D-Glucan After Antiretroviral Therapy and Association With Adiposity. (Pubmed Central) - Nov 19, 2019
This may represent continued intestinal damage during ART and resulting fungal translocation. Higher BDG was associated with larger fat gains on ART.
- | Prezista (darunavir) / J&J
Journal: The pharmacokinetic properties of HIV-1 protease inhibitors: A computational perspective on herbal phytochemicals. (Pubmed Central) - Nov 18, 2019
Epigallocatechin gallate and Kaempferol-7-glucoside exhibited pronounced structural evidence as potential HIV-1 protease enzyme inhibitors. This study acts as a steppingstone toward the use of natural products against diseases that are plagued with adverse drug-interactions.
- |||| Prezista (darunavir) / J&J, Pifeltro (doravirine) / Merck (MSD)
Clinical, Head-to-Head: Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial - @TheLancetHIV Interesting but does it matter today? https://t.co/0wjocZEJcm (Twitter) - Nov 18, 2019
- Use of ibalizumab in a heavily treatment-experienced HIV-1-infected subject harbouring a multidrug-resistant virus (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_2147;
A Genotyping Susceptibility Tests (GSTs) was performed and, according to the Stanford HIVdb interpretation, identified: - on plasma RNA: susceptibility to doravirine (DOR)/etravirine (ETV)/rilpivirine (RPV), all integrase strand transfer inhibitors (INSTIs) and enfuvirtide (ENF); different degrees of resistance to DRV/r, all nucleoside reverse transcriptase inhibitors (NRTIs); a R5-tropic virus was found; - on blood DNA: susceptibility to DRV/r and emtricitabine (FTC)/abacavir (ABC); different degrees of resistance to tenofovir(TDF)/ABC, DOR/ETV, RPV, dolutegravir (DTG), ENF; a X4-tropic virus was found...Thanks to the “5% Fund” of the Italian Medicines Agency, this man received an initial loading dose of IBA (2000 mg/iv) followed by maintenance doses (800 mg/iv every 15 days) in association with a recycling regimen including FTC/RPV/tenofovir alafenamide 200/25/25 mg QD, DTG 50 mg BID, maraviroc 150 mg BID, ENF 90 mg BID (replaced with DRV/r 600/100 mg BID after 12 weeks to improve acceptability)...In this man IBA, plus an OBT with residual antiviral activity, favoured the achievement of virological control, at least in the short-term. Management of patients with no fully active drugs is an unmet clinical need and novel classes such as CD4-binding monoclonal antibodies may have a key role.
- Prezista (darunavir) / J&J, bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Rapid ART start in primary HIV infection: time to viral suppression in a London cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_2074;
Rapid start with INSTI regimens results in quicker viral suppression than with PI-based regimens in PHI, even when PIs are subsequently switched to INSTIs. Concerns about lack of a baseline VRT result prior to rapid ART start may potentially be overcome by the use of the newer INSTIs with a high genetic barrier such as dolutegravir and bictegravir.
- Prezista (darunavir) / J&J, emtricitabine/tenofovir disoproxil fumarate / Generic Mfg., Vitekta (elvitegravir) / Japan Tobacco, Gilead
Evaluation of the “test and treat” strategy in an high-income setting: data from a multicenter Italian cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1978;
We enrolled 196 patients from 9 Italian clinical centers: 120 patients started a triple therapy with tenofovir/emtricitabine plus an integrase inhibitor (83 with dolutegravir, 21 with elvitegravir and 16 with raltegravir), 32 with abacavir/lamivudine/dolutegravir, 17 with tenofovir/emtricitabine plus boosted darunavir, 11 with tenofovir/emtricitabine plus rilpivirine. In our cohort, we did not observe an advantage in using a one-day treatment approach compared to other strategies of ARV initiation.
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Comparative neuropsychiatric toxicity profile of dolutegravir (DTG) versus efavirenz (EFV) versus other antiretroviral third drugs used either in first-line or switch antiretroviral therapies (ART): data from Icona Foundation Study Cohort (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1851;
We included all ART-naive or virologically-suppressed treatment-experienced HIV+ patients, enrolled in the Icona cohort, who started or switched to an antiretroviral regimen including DTG or EFV or other currently used third drugs (boosted darunavir, atazanavir, rilpivirine or other integrase strand transfer inhibitors [INSTIs]). In this large cohort, both ART-naïve and treatment-experienced patients on DTG-based regimens showed a risk of experiencing treatment-limiting NPAES significantly lower than patients on EFV-based regimens but higher than people on non-EFV non-DTG ART.
- Prezista (darunavir) / J&J, lamivudine / Generic Mfg., Tivicay (dolutegravir) / ViiV Healthcare
Weight gain in people living with HIV switched to dual therapy with dolutegravir plus rilpivirine: changes in body fat mass (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1847;
P=N/A
Nevertheless, comparable changes were observed in individuals switching to darunavir plus lamivudine. Fat mass increase was associated with baseline fat mass and immunological status.
- Predictors of weight gain in patients treated with dolutegravir (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1844;
In SCOLTA the use of TDF/FTC resulted as independent factor associated with weight gain in PLWHIV treated with DTG. Male patients with lower baseline weight and lower CD4 were those more prone to gain weight.
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Risk Factors associated to immune reconstitution inflammatory syndrome (IRIS) in HIV-infected hospitalized patients with advanced disease (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1796;
Detectable viral load, AIDS cause of admission and unknown HIV infection were associated to IRIS in our cohort. Efavirenz and dolutegravir could be most related drugs to IRIS but further investigations are needed.
- Selzentry (maraviroc) / ViiV Healthcare, Prezista (darunavir) / J&J
Whole body MRI detects high prevalence of incidental findings in older HIV-1-infected patients participating in a randomised, controlled trial of maraviroc and/or metformin for non-alcoholic fatty liver disease (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1740;
This emphasises, first, the importance of ensuring a rapid-reporting system for trials with imaging endpoints, in particular where whole body scans are performed. Second, that there may be a role for WB-MRI screening in an ageing population of HIV-infected patients especially as the sensitivity/specificity of WB-MRI continues to improve.
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Central nervous system penetration of antiretroviral drugs in HIV-positive patients with neurocognitive impairment, assessed from paired plasma-CSF concentrations (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1717;
Free fraction is an imperfect proxy for CSF concentration. The impact of ARVs' CSF penetration on the development of NCI is inconclusive.
- Drug-drug interactions between antiretrovirals and carbamazepine or oxcarbazepine: a real-life investigation (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1714;
Coadministration of carbamazepine or oxcarbazepine with atazanavir or dolutegravir should be avoided; for these two drugs, the adoption of TDM is strongly advisable, eventually combined with increased antiretroviral doses. [FIgure 1]
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Ritonavir-boosted darunavir plus two nucleoside reverse transcriptase inhibitors versus other regimens for initial antiretroviral therapy for people with HIV infection: a systematic review (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1710;
At 96 weeks, DRV/r underperformed raltegravir (RR 0.94, 95% CI 0.88-0.99) but was similar to ritonavir-boosted atazanavir (RR 1.02, 95% CI 0.96-1.09)...Interpretation. Initial ART regimens using DRV/r should be considered in future World Health Organization guidelines.
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
No metabolic or renal benefits when switching to an NRTI-free dolutegravir-containing 2 drug regimen (2DR) - a subanalysis of the DUALIS study (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1697;
Purpose: The DUALIS study assessed efficacy and safety of switching to Dolutegravir (DTG) and boosted darunavir (bDRV) (2DR) and has demonstrated non-inferiority as compared to 2 NRTI+bDRV (3DR). While being non-inferior with regard to virologic suppression, a switch to a 2DR consisting of DTG+bDRV does not yield significant metabolic or renal advantages by substituting the NRTI components of a comparative 3DR antiretroviral therapy.
- Prezista (darunavir) / J&J, Pifeltro (doravirine) / Merck (MSD), lamivudine / Generic Mfg.
Biologic sex is not the only difference between men and women: data from the Doravirine phase 2/3 clinical trials (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1696;
Although women had similar efficacy and safety results, women represented 15% of participants. Increased enrollment of women in clinical trials or women-only trials should be considered to further understand antiretroviral efficacy and safety in this important population.
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
A switch to dolutegravir in combination with boosted darunavir is safe and effective in suppressed patients with HIV - a predefined psychosocial subanalysis of the DUALIS study (Exhibition hall) - Nov 15, 2019 - Abstract #EACS2019EACS_1694;
A switch to a 2DR regimen consisting of DTG+bDRV does not lead to any significant differences, neither in anxiety nor depression, nor in HRQoLoutcome measures. [Forest plot of HADS and MOS-HIV outcomes with Odds ratio (OR) and corresponding 95% CI]